21012 ⎘
Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Blood coagulation or fibrinolysis factors Factors VIII
FACTOR VIII POLYPEPTIDE FORMULATIONS
#2METHODS FOR IMPROVED THERAPEUTIC USE OF RECOMBINANT AAV
#3SUPPLEMENTATION OF LIVER ENZYME EXPRESSION
#4SUPPLEMENTATION OF LIVER ENZYME EXPRESSION
#5SUPPLEMENTATION OF LIVER ENZYME EXPRESSION
#6GLYCOTARGETING THERAPEUTICS
#7VARIANTS OF COAGULATION FACTOR VIII AND USES THEREOF
#8USE OF LENTIVIRAL VECTORS EXPRESSING FACTOR VIII
#9ENGINEERED LIVER-SPECIFIC CORE PROMOTERS AND THEIR APPLICATIONS
#10TREATMENT OF COAGULATION DISEASE BY ADMINISTRATION OF RECOMBINANT VWF
#11Compositions of DNA Molecules Encoding Factor VIII, Methods of Making Thereof, and Methods of Use Thereof
#12Adeno-Associated Virus Factor VIII Vectors
#13ENGINEERING B CELL-BASED PROTEIN FACTORIES TO TREAT SERIOUS DISEASES
#14CODON-OPTIMIZED NUCLEIC ACID ENCODING THE FVIII-BDD
#15NUCLEIC ACID HAVING PROMOTER ACTIVITY AND USE THEREOF
#16GENE THERAPY FOR BLEEDING DISORDERS
#17METHODS AND COMPOSITIONS FOR RE-DOSING AAV USING ANTI-CD40 ANTAGONISTIC ANTIBODY TO SUPPRESS HOST ANTI-AAV ANTIBODY RESPONSE
#18METHODS FOR TREATING HEMOPHILIA A AND POPULATION PHARMACOKINETICS TOOLS FOR DETERMINING TREATMENTS AND USES THEREOF
#19METHODS OF INDUCING IMMUNE TOLERANCE TO CLOTTING FACTORS
#20COMPOSITIONS AND METHODS FOR MODULATING FACTOR VIII FUNCTION
#21METHODS AND COMPOSITIONS FOR USING PLASMA CELL DEPLETING AGENTS AND/OR B CELL DEPLETING AGENTS TO SUPPRESS HOST ANTI-AAV ANTIBODY RESPONSE AND ENABLE AAV TRANSDUCTION AND RE-DOSING
#22COMPOSITIONS AND METHODS
#23FACTOR VIII CHIMERIC AND HYBRID POLYPEPTIDES, AND METHODS OF USE THEREOF
#24CLOTTING FACTOR PREPARATIONS FOR DELIVERY INTO TISSUE OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE
#25METHODS RELATED TO ADMINISTERING IMMUNOSUPPRESSANTS AND THERAPEUTIC MACROMOLECULES AT A REDUCED PHARMACODYNAMICALLY EFFECTIVE DOSE
#26CpG REDUCED FACTOR VIII VARIANTS, COMPOSITIONS AND METHODS AND USES FOR TREATMENT OF HEMOSTASIS DISORDERS
#27SUPPLEMENTATION OF LIVER ENZYME EXPRESSION
#28MODULAR BIOMATERIAL PLATFORM LOCAL, INJECTABLE DELIVERY OF A DRUG AND METHODS OF MAKING AND USING SAME
#29ENGINEERED LIVER-SPECIFIC ENHANCERS AND THEIR APPLICATIONS
#30METHODS OF TREATING HEMOPHILIC ARTHROPATHY USING CHIMERIC CLOTTING FACTORS
#31Factor VIII Sequences
#32Apparatus for Improving Hydration and/or Reducing Particle Size of a Product and a Method of Use Thereof
#33FACTOR VIII (FVIII) GENE THERAPY METHODS
#34HIGHLY SOLUBLE FIBRINOGEN COMPOSITIONS
#35SYSTEMS FOR EXTRACTING PROTEINS FROM A BLOOD-BASED MATERIAL
#36MODIFIED COLLOIDAL PARTICLES FOR USE IN THE TREATMENT OF HAEMOPHILIA A
#37GENE THERAPY OF HEMOPHILIA A USING VIRAL VECTORS ENCODING RECOMBINANT FVIII VARIANTS WITH INCREASED EXPRESSION
#38MODIFIED COLLOIDAL PARTICLES FOR USE IN THE TREATMENT OF HAEMOPHILIA A
#39MODIFIED COLLOIDAL PARTICLES FOR USE IN THE TREATMENT OF HAEMOPHILIA A
#40FORMULATIONS OF FACTOR VIII CHIMERIC PROTEINS AND USES THEREOF
#41METHODS OF ADMINISTERING IMMUNOSUPPRESSANTS HAVING A SPECIFIED PHARMACODYNAMIC EFFECTIVE LIFE AND THERAPEUTIC MACROMOLECULES FOR THE INDUCTION OF IMMUNE TOLERANCE
#42METHOD FOR PRODUCING HUMAN PLASMA-DERIVED FACTOR VIII / VON WILLEBRAND FACTOR AND COMPOSITION OBTAINED
#43TREATMENT OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE BY ADMINISTRATION OF RECOMBINANT VWF
#44STABLE EXPRESSION OF AAV VECTORS IN JUVENILE SUBJECTS
#45GENE THERAPY OF HEMOPHILIA A USING VIRAL VECTORS ENCODING RECOMBINANT FVIII VARIANTS WITH INCREASED EXPRESSION
#46CLOTTING FACTOR PREPARATIONS FOR DELIVERY INTO TISSUE OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE
#47IMMUNE TOLERANCE INDUCTION AND ERADICATION OF ANTI-DRUG ANTIBODIES (ADA) TO THERAPEUTIC FACTOR VIII
#48POPULATION PHARMACOKINETICS TOOLS AND USES THEREOF
#49COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS
#50LIQUID COMPOSITION COMPRISING FACTOR VIII OR FACTOR VIII/VON WILLEBRAND FACTOR COMPLEX
#51Post-Natal Transplantation Of Factor VIII-Expressing Cells For Treatment of Hemophilia
#52Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
#53LYOPHILIZED POLYMER SCAFFOLD COMPOSITIONS, PROCESSES FOR PREPARATION AND USE IN ANABOLIC WOUND REPAIR
#54THROMBIN CLEAVABLE LINKER WITH XTEN AND ITS USES THEREOF
#55CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS
#56IMPROVED PHARMACEUTICAL COMPOSITIONS CONTAINING ADENO-ASSOCIATED VIRAL VECTOR
#57Adeno-Associated Virus Factor VIII Vectors, Associated Viral Particles and Therapeutic Formulations Comprising the Same
#58TREATMENTS FOR HEMOPHILIA A
#59De-immunized factor VIII molecule and pharmaceutical compositions comprising the same
#60GENE THERAPY FOR TREATING HEMOPHILIA A
#61COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS
#62TREATMENT OF MENORRHAGIA IN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE BY ADMINISTRATION OF RECOMBINANT VWF
#63COMPOSITION FOR INCREASING EXPRESSION OF BLOOD COAGULATION FACTOR GENE, COMPRISING CORE-SHELL STRUCTURED MICROPARTICLES AS ACTIVE INGREDIENT
#64Particles for Targeted Delivery and Uses in Managing Bleeding or Blood Clotting
#65RECOMBINANT FACTOR VIII PROTEINS
#66CONJUGATES OF BIOLOGICALLY ACTIVE MOLECULES TO FUNCTIONALIZED POLYMERS
#67CONJUGATES OF A FACTOR VIII MOIETY HAVING AN OXIME-CONTAINING LINKAGE
#68Factor VIII Sequences
#69SUBCUTANEOUS ADMINISTRATION OF FACTOR VIII
#70Factor VIII zwitterionic polymer conjugates
#71HIGH CONCENTRATED PROTEIN COMPOSITIONS FOR PREVENTING TISSUE ADHESION
#72Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
#73LIVER-SPECIFIC CONSTRUCTS, FACTOR VIII EXPRESSION CASSETTES AND METHODS OF USE THEREOF
#74GLYCOTARGETING THERAPEUTICS
#75POLYMER DERIVATIVES HAVING PARTICULAR ATOM ARRANGEMENTS
#76Particles for targeted delivery and uses in managing bleeding or blood clotting
#77METHODS PROVIDING A THERAPEUTIC MACROMOLECULE AND SYNTHETIC NANOCARRIERS COMPRISING IMMUNOSUPPRESSANT LOCALLY AND CONCOMITANTLY TO REDUCE BOTH TYPE 1 AND TYPE IV HYPERSENSITIVITY
#78Conjugates of tumor necrosis factor inhibitors to functionalized polymers
#79Vectors for Liver-Directed Gene Therapy of Hemophilia and Methods and Use Thereof
#80CHIMERIC FACTOR VIII POLYPEPTIDES AND USES THEREOF
#81METHODS OF REDUCING IMMUNOGENICITY AGAINST FACTOR VIII IN INDIVIDUALS UNDERGOING FACTOR VIII THERAPY
#82Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
#83Methods for Extracting Proteins from a Blood-Based Material
#84METHODS OF TREATMENT RELATED TO COMPLEXES OF VON WILLEBRAND FACTOR AND COMPLEMENT C1Q
#85METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (rVWF)
#86TRANSCRIPTION REGULATORY ELEMENTS
#87METHODS FOR IMPROVED THERAPEUTIC USE OF RECOMBINANT AAV
#88HUMAN GENE THERAPY METHODS FOR HEMOPHILIA A
#89Adeno-associated virus factor VIII vectors
#90Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression
#91ISOLATED MODIFIED VP1 CAPSID PROTEIN OF AAV5
#92STABILIZING BUFFER FOR FACTOR VIII AND VWF
#93METHOD FOR THE MANUFACTURE OF A DOSAGE FORM WITH MUCOADHESIVE PROPERTIES FOR BUCCAL ADMINISTRATION OF BIOLOGICS
#94FACTOR VIII-FC CHIMERIC AND HYBRID POLYPEPTIDES, AND METHODS OF USE THEREOF
#95RECOMBINANT FACTOR VIII-FC FOR TREATING HEMOPHILIA AND LOW BONE MINERAL DENSITY
#96CLOTTING FACTOR PREPARATIONS FOR DELIVERY INTO TISSUE OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE
#97THROMBIN CLEAVABLE LINKER WITH XTEN AND ITS USES THEREOF
#98METHODS OF ADMINISTERING IMMUNOSUPPRESSANTS HAVING A SPECIFIED PHARMACODYNAMIC EFFECTIVE LIFE AND THERAPEUTIC MACROMOLECULES FOR THE INDUCTION OF IMMUNE TOLERANCE
#99FACTOR VIII COMPLEX WITH XTEN AND VON WILLEBRAND FACTOR PROTEIN, AND USES THEREOF
#100Stabilised Compositions of Factor VII Polypeptides
#101Conjugates of tumor necrosis factor inhibitors to functionalized polymers
#102EXPOSED COLLAGEN-TARGETED FUSION CYTOKINE FOR IMMUNE MODULATION IN INVASIVE CANCERS AND LESIONS OF INFECTIONS
#103IMPLANTABLE DEVICES FOR CELL THERAPY AND RELATED METHODS
#104POLYMER-FACTOR VIII MOIETY CONJUGATES
#105INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES
#106Optimized Liver-Specific Expression Systems for FVIII and FIX
#107Conjugates of a factor VIII moiety having an oxime-containing linkage
#108IMPROVED FVIII FUSION PROTEIN AND USE THEREOF
#109Method for improving the stability of purified Factor VIII after reconstitution
#110Conjugates of biologically active molecules to functionalized polymers
#111Polypeptides modulating SIGLEC dependent immune responses
#112Truncated von Willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
#113Methods for extracting proteins from a blood-based material
#114CRYOPRECIPITATE COMPOSITIONS AND METHODS OF PREPARATION THEREOF
#115Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
#116CONCEPTS FOR THE TREATMENT OF GENETIC DISORDERS WITH HIGH-CAPACITY PLAL-GENERATED GOLD NANOPARTICLES
#117IMPROVED CLINICAL PARAMETERS BY EXPRESSION OF FACTOR VIII
#118Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
#119METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS
#120Methods for preparing modified von Willebrand Factor
#121Method of producing recombinant high molecular weight vWF in cell culture
#122Composition for increasing the expression of a growth factor gene, comprising coreshell structured microparticles as active ingredient
#123COMPOSITION FOR INCREASING EXPRESSION OF BLOOD COAGULATION FACTOR GENE, COMPRISING CORE-SHELL STRUCTURED MICROPARTICLES AS ACTIVE INGREDIENT
#124FACTOR VIII POLYPEPTIDE FORMULATIONS
#125USE OF LENTIVIRAL VECTORS EXPRESSING FACTOR VIII
#126Aldehyde Tags, Uses Thereof in Site-Specific Protein Modification
#127Optimised coding sequence and promoter
#128MUTEINS OF CLOTTING FACTOR Vlll
#129Factor VIII sequences
#130Methods for preparing modified von Willebrand factor
#131TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE OR PREVENT ANAPHYLAXIS IN RESPONSE TO A NON-ALLERGENIC ANTIGEN
#132Conjugates of tumor necrosis factor inhibitors to functionalized polymers
#133Particles for targeted delivery and uses in managing bleeding or blood clotting
#134METHODS AND COMPOSITIONS RELATED TO LONG HALF-LIFE COAGULATION COMPLEXES
#135COMPOSITIONS AND METHODS FOR SUPPRESSION OF INHIBITOR FORMATION AGAINST COAGULATION FACTORS IN HEMOPHILIA PATIENTS
#136Method for improving the stability of purified Factor VIII after reconstitution
#137POLYNUCLEOTIDES ENCODING COAGULATION FACTOR VIII
#138Factor VIII zwitterionic polymer conjugates
#139Methods of prophylactic treatment using recombinant VWF (rVWF)
#140Method of preparing composition containing factor VIII (FVIII) and von Willebrand factor (vWF) with controlled content of von Willebrand factor (vWF)
#141Polymer derivatives having particular atom arrangements
#142FACTOR VIII (FVIII) GENE THERAPY METHODS
#143Conjugates of biologically active molecules to functionalized polymers
#144Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
#145Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
#146METHOD FOR VIRUS FILTRATION OF VON WILLEBRAND FACTOR
#147Modulation of FVIII immunogenicity by truncated VWF
#148Low concentrated protein compositions for preventing tissue adhesion
#149High concentrated protein compositions for preventing tissue adhesion
#150Glycotargeting therapeutics
#151COMPOSITIONS AND METHODS FOR WOUND CLOSURE
#152METHODS RELATED TO ADMINISTERING IMMUNOSUPPRESSANTS AND THERAPEUTIC MACROMOLECULES AT A REDUCED PHARMACODYNAMICALLY EFFECTIVE DOSE
#153DELIVERY METHODS AND COMPOSITIONS FOR NUCLEASE-MEDIATED GENOME ENGINEERING
#154Adeno-associated virus factor VIII vectors
#155Gene therapy for treating hemophilia A
#156Methods of inducing immune tolerance to clotting factors
#157Factor VIII formulations
#158Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivity
#159STABLE EXPRESSION OF AAV VECTORS IN JUVENILE SUBJECTS
#160METHODS COMPRISING DOSING COMBINATIONS FOR REDUCING UNDESIRED HUMORAL IMMUNE RESPONSES
#161METHODS OF ADMINISTERING IMMUNOSUPPRESSANTS HAVING A SPECIFIED PHARMACODYNAMIC EFFECTIVE LIFE AND THERAPEUTIC MACROMOLECULES FOR THE INDUCTION OF IMMUNE TOLERANCE
#162Adeno-associated virus Factor VIII vectors, associated viral particles and therapeutic formulations comprising the same
#163Recombinant factor VIII proteins
#164Stabilised Compositions of Factor VII Polypeptides
#165Novel Use of Von Willebrand Factor
#166Conjugates of tumor necrosis factor inhibitors to functionalized polymers
#167Methods of treating hemophilic arthropathy using chimeric clotting factors
#168Cyclodextrins as procoagulants
#169Highly glycosylated human blood-clotting factor VIII fusion protein, and manufacturing method and application of same
#170POPULATION PHARMACOKINETICS TOOLS AND USES THEREOF
#171PROTECTING COMPOSITIONS FOR RECOMBINANTLY PRODUCED FACTOR VIII
#172Gene therapy for treating hemophilia A
#173Blood coagulation protein conjugates
#174SINGLE-DOSE ADMINISTRATION OF FACTOR VIIa
#175Allelic variants of human factor VIII
#176Promoter for cell-specific gene expression and uses thereof
#177Truncated von Willebrand Factor polypeptides for treating hemophilia
#178Factor VIII-FC chimeric and hybrid polypeptides, and methods of use thereof
#179Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
#180Vectors for liver-directed gene therapy of hemophilia and methods and use thereof
#181FVIII Formulation
#182Polypeptides modulating SIGLEC dependent immune responses
#183Compositions and methods for suppression of inhibitor formation against coagulation factors in hemophilia patients
#184Factor VIII polymer conjugates
#185Glycosylated VWF fusion proteins with improved pharmacokinetics
#186Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
#187MODIFIED BLOOD FACTORS COMPRISING A LOW DEGREE OF WATER SOLUBLE POLYMER
#188Aldehyde tags, uses thereof in site-specific protein modification
#189Liver-specific constructs factor VIII expression cassettes and methods of use thereof
#190FACTOR VIII VARIANTS, NUCLEIC ACID SEQUENCES, AND METHODS AND USES FOR TREATMENT OF HEMOSTASIS DISORDERS
#191Liver-specific constructs and methods of use thereof
#192Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
#193Conjugates of biologically active molecules to functionalized polymers
#194Single dose administration of factor VIIa
#195Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
#196Method of producing recombinant high molecular weight vWF in cell culture
#197Pharmaceutical formulations of PEGylated liposomes and blood coagulation factors
#198Methods for extracting proteins from a blood-based material
#199Method for improving the stability of purified factor VIII after reconstitution
#200STABILIZING AGENT FOR PHARMACEUTICAL PROTEINS
#201Polymer derivatives having particular atom arrangements
#202Mutated truncated von Willebrand Factor
#203SINGLE-DOSE ADMINISTRATION OF FACTOR VIIa
#204Conjugates of tumor necrosis factor inhibitors to functionalized polymers
#205Stabilised Compositions of Factor VII Polypeptides
#206Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
#207INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES
#208CpG REDUCED FACTOR VIII VARIANTS, COMPOSITIONS AND METHODS AND USES FOR TREATMENT OF HEMOSTASIS DISORDERS
#209Method of treating hemophilia A
#210Glycotargeting therapeutics
#211Method of making a water-soluble polymer-factor VIII moiety conjugate
#212Methods and compositions related to long half-life coagulation complexes
#213Exposed collagen-targeted fusion cytokine for immune modulation in invasive cancers and lesions of infections
#214Glycopolysialylation of non-blood coagulation proteins
#215Method to achieve extended expression of DNA infused into liver
#216Preparation comprising factor VIII and Von Willebrand factor peptides
#217Compounds Suitable for Treatment of Haemophilia
#218ADENO-ASSOCIATED VIRUS FACTOR VIII VECTORS
#219Truncated von Willebrand factor polypeptides for treating hemophilia
#220Methods for preparing modified von Willebrand factor
#221Variant factor VIII polypeptides and methods of their production and use
#222Use of von Willebrand factor
#223COVALENT COMPLEX OF VON WILLEBRAND FACTOR AND FACTOR VIII, COMPOSITIONS, AND USES RELATING THERETO
#224Optimized liver-specific expression systems for FVIII and FIX
#225Method of producing recombinant high molecular weight vWF in cell culture
#226COMPOUNDS FOR IMPROVING THE HALF-LIFE OF VON WILLEBRAND FACTOR
#227Optimised subcutaneous therapeutic agents
#228Optimised coding sequence and promoter
#229Use of PLL for improving the stability of molecules in solution
#230Pharmaceutical Formulations of PEGylated Liposomes and Blood Coagulation Factors
#231Factor VIII polypeptide formulations
#232NON-ANTICOAGULANT SULFATED OR SULFONATED SYNTHETIC POLYMERS
#233FVIII PEPTIDES FOR IMMUNE TOLERANCE INDUCTION AND IMMUNODIAGNOSTICS
#234Factor VIII formulation
#235CpG reduced factor VIII variants, compositions and methods and uses for treatment of hemostasis disorders
#236IMPROVED FACTOR VIII PREPARATIONS SUITABLE FOR THERAPEUTIC USE AND PROCESSES TO OBTAIN THESE
#237PROTECTING COMPOSITIONS FOR RECOMBINANTLY PRODUCED FACTOR VIII
#238Routine laboratory and point-of-care (POC) testing for hemostasis
#239Modified von Willebrand Factor
#240Uses of Humanized Cobra Venom Factor for Reducing or Preventing Immunogenicity
#241Aldehyde tags, uses thereof in site-specific protein modification
#242Liver-specific constructs, factor VIII expression cassettes and methods of use thereof
#243Method of Administering Porcine B-Domainless fVIII
#244Lentiviral vectors
#245Adeno-associated virus factor VIII vectors
#246Adeno-associated virus factor VIII vectors, associated viral particles and therapeutic formulations comprising the same
#247Factor VIII formulations
#248Stabilization of factor VIII without calcium as an excipient
#249COPOLYMERS OF FORMULA (I) AND USES
#250Stable Factor VIII formulations with low sugar-glycine
#251Lyophilized polymer scaffold compositions, processes for preparation and use in anabolic wound repair
#252Targeted coagulation factors and method of using the same
#253Methods of delivering factor VIII encoding nucleic acid sequences
#254Cryoprecipitate compositions and methods of preparation thereof
#255Factor VIII Molecules with Reduced VWF Binding
#256Delivery methods and compositions for nuclease-mediated genome engineering
#257Method of producing recombinant high molecular weight vWF in cell culture
#258Glycotargeting therapeutics
#259Albumin-free factor VIII formulations
#260LIPID NANODISCS AND NANORODS AS MODULATORS OF CLOTTING FACTOR FUNCTION IN VIVO
#261Method for improving the stability of purified factor VIII after reconstitution
#262Blood coagulation protein conjugates
#263Recombinant factor VIII proteins
#264Conjugates of tumor necrosis factor inhibitors to functionalized polymers
#265Method for preparing a polymeric reagent
#266Compounds Suitable for Treatment of Haemophilia
#267Population pharmacokinetics tools and uses thereof
#268Compositions and methods for suppression of inhibitor formation against coagulation factors in hemophilia patients
#269Method to concentrate von willebrand factor or complexes thereof
#270COMPOSITIONS FOR INDUCING IMMUNE TOLERANCE TO COAGULATION FACTOR PROTEINS
#271Stabilized Factor VIII Variants
#272Stabilizing agent for pharmaceutical proteins
#273THROMBIN CLEAVABLE LINKER WITH XTEN AND ITS USES THEREOF
#274METHOD OF TREATING HAEMOPHILIA BY INDUCING TOLERANCE TO BLOOD FACTORS
#275Compounds Suitable for Treatment of Haemophilia
#276FACTOR VIII: REMODELING AND GLYCOCONJUGATION OF FACTOR VIII
#277Covalent complex of von Willebrand Factor and factor VIII, compositions, and uses relating thereto
#278MODIFIED BLOOD FACTORS COMPRISING A LOW DEGREE OF WATER SOLUBLE POLYMER
#279Factor VIII zwitterionic polymer conjugates
#280Factor VIII-Fc Chimeric and Hybrid Polypeptides, and Methods of Use Thereof
#281Factor VIII-XTEN fusions and uses thereof
#282FACTOR VIII: REMODELING AND GLYCOCONJUGATION OF FACTOR VIII
#283TREATMENT OF COAGULATION DISEASE BY ADMINISTRATION OF RECOMBINANT VWF
#284Polymer-factor VIII moiety conjugates
#285Modified Glycoproteins Having Circulating Half-Lives
#286BLOOD COAGULATION PROTEIN CONJUGATES
#287Pharmaceutical Composition Suitable for Treatment of Haemophilia
#288Factor VIII Conjugates
#289Treatment of bleeding with low half-life fibrinogen
#290SINGLE-DOSE ADMINISTRATION OF FACTOR VIIa
#291THERAPEUTIC PEPTIDE-EXPRESSING CELLS
#292Methods and Compositions for Treating Bleeding Disorders
#293FACTOR VIII POLYMER CONJUGATES
#294METHODS OF TREATING HEMOPHILIA IN PATIENTS HAVING DEVELOPED INHIBITORY ANTIBODIES
#295PREDICTING AND REDUCING ALLOIMMUNOGENICITY OF PROTEIN THERAPEUTICS
#296Variant factor VIII polypeptides and methods of their production and use
#297TARGETED ELIMINATION OF FACTOR VIII IMMUNE CELLS
#298RECOMBINANT FACTOR VIII FORMULATIONS
#299Liquid Factor VIII Formulations
#300Factor VIII Molecules With Reduced VWF Binding